Recombinant Fusion Proteins
"Recombinant Fusion Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
| Descriptor ID |
D011993
|
| MeSH Number(s) |
D12.776.828.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Recombinant Fusion Proteins".
Below are MeSH descriptors whose meaning is more specific than "Recombinant Fusion Proteins".
This graph shows the total number of publications written about "Recombinant Fusion Proteins" by people in this website by year, and whether "Recombinant Fusion Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1995 | 0 | 3 | 3 |
| 1996 | 0 | 3 | 3 |
| 1997 | 2 | 8 | 10 |
| 1998 | 0 | 6 | 6 |
| 1999 | 0 | 10 | 10 |
| 2000 | 0 | 10 | 10 |
| 2001 | 3 | 6 | 9 |
| 2002 | 0 | 10 | 10 |
| 2003 | 3 | 8 | 11 |
| 2004 | 1 | 7 | 8 |
| 2005 | 1 | 2 | 3 |
| 2006 | 1 | 12 | 13 |
| 2007 | 3 | 6 | 9 |
| 2008 | 1 | 8 | 9 |
| 2009 | 3 | 8 | 11 |
| 2010 | 2 | 5 | 7 |
| 2011 | 1 | 2 | 3 |
| 2012 | 2 | 3 | 5 |
| 2013 | 3 | 4 | 7 |
| 2014 | 0 | 2 | 2 |
| 2015 | 3 | 2 | 5 |
| 2016 | 1 | 2 | 3 |
| 2017 | 0 | 2 | 2 |
| 2018 | 4 | 1 | 5 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 2 | 3 |
| 2021 | 2 | 1 | 3 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles.
-
Patient adherence to therapy after switch to aflibercept from bevacizumab or ranibizumab for treatment-refractory neovascular age-related macular degeneration. Indian J Ophthalmol. 2024 Jan 01; 72(Suppl 1):S101-S105.
-
A novel membrane targeting domain mediates the endosomal or Golgi localization specificity of small GTPases Rab22 and Rab31. J Biol Chem. 2022 09; 298(9):102281.
-
Rapid screening of high expressing Escherichia coli colonies using a novel dicistronic-autoinducible system. Microb Cell Fact. 2021 Dec 11; 20(1):223.
-
Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology (Oxford). 2021 11 03; 60(11):5379-5389.
-
Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis. Ann Pharmacother. 2022 05; 56(5):572-581.
-
Intraocular pressure decreases in eyes with glaucoma-related diagnoses after conversion to aflibercept for treatment-resistant age-related macular degeneration. Eye (Lond). 2022 Sep; 36(9):1813-1819.
-
CNS Autoimmune Responses in BCMA-Deficient Mice Provide Insight for the Failure of Atacicept in MS. Neurol Neuroimmunol Neuroinflamm. 2021 05; 8(3).
-
Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders. Front Immunol. 2020; 11:592639.
-
Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study. Rheumatology (Oxford). 2020 10 01; 59(10):2930-2938.
-
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer. 2020 06 15; 126(12):2821-2828.